- Insulin resistance: a metabolic pathway to chronic liver diseaseElisabetta Bugianesi
Gastroenterology Department, University of Turin, Turin, Italy
Hepatology 42:987-1000. 2005..Finally, the ability of insulin-sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed...
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetesAnna Ludovica Fracanzani
Department of Internal Medicine, Scientific Institute of Recovery and Cure Foundation IRCCS, Hospital Maggiore Policlinico, University of Milan, Milan, Italy
Hepatology 48:792-8. 2008..07; 95% CI, 1.02-1.14), and diabetes (OR, 1.8; 95% CI, 1.4-2.3) in the overall series, serum ferritin and diabetes in those with increased ALT, and only HOMA-IR (OR, 1.97; 95% CI, 1.2-3.7) in patients with normal ALT...
- Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinomaElisabetta Bugianesi
Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
Gastroenterology 123:134-40. 2002..Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown...
- A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver diseaseElisabetta Bugianesi
Department of Gastroenterology, University of Turin, Italy
Am J Gastroenterol 100:1082-90. 2005..We aimed to compare the usefulness of metformin versus prescriptive diet or vitamin E...
- Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis CEster Vanni
Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
Hepatology 50:697-706. 2009..The decreased insulin-stimulated suppression of EGP was associated with increased hepatic suppressor of cytokine signaling 3 (SOCS3; P < 0.05) and interleukin-18 (P < 0.05) expression...
- Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort studyChiara Giordanino
Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
Dig Liver Dis 44:406-12. 2012....
- NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetesElisabetta Bugianesi
Division of Gastro Hepatology, University of Turin, S Giovanni Battista Hospital, Corso Bramante 88, Turin 10126, Italy
Curr Diab Rep 7:175-80. 2007..Although cardiovascular risk remains the major cause for excess mortality in type 2 diabetes mellitus, the risk of progressive liver disease should no longer be underscored...
- Hepatic and cardiac steatosis: are they coupled?Elisabetta Bugianesi
Division of Gastro Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy
Heart Fail Clin 8:663-70. 2012..Collectively these findings suggest the presence of complex and intertwined interrelationships between NAFLD, myocardial steatosis, and coronary artery disease...
- Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort studyChiara Giordanino
Gastroenterology, Molinette Hospital, Turin, Italy
Am J Gastroenterol 103:2481-7. 2008..Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy...
- Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosisElisabetta Bugianesi
Gastroenterology Department, University of Turin, Italy
Hepatology 44:1648-55. 2006..Virus-induced hepatic steatosis as seen in CHC-3 does not contribute significantly to liver fibrosis...
- Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis CGianluca Svegliati-Baroni
Department of Gastroenterology, Polytechnic University of Marche, Ancona, Italy
Gut 60:108-15. 2011..To study the mechanism(s) linking insulin resistance (IR) to hepatic fibrosis and the role of the epithelial component in tissue repair and fibrosis in chronic hepatitis C (CHC)...
- The interaction of metabolic factors with HCV infection: does it matter?Elisabetta Bugianesi
Department of Internal Medicine, University of Turin, Italy
J Hepatol 56:S56-65. 2012..Thus, targeted lifestyle and pharmacological measures are urgently warranted in chronic hepatitis C with metabolic alterations...
- Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severityElisabetta Bugianesi
Division of Gastroenterology, University of Turin, Ospedale San Giovanni Battista, Corso Bramante 88, I 10126 Torino, Italy
J Clin Endocrinol Metab 90:3498-504. 2005..Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by ectopic fat accumulation in the central compartment...
- From the metabolic syndrome to NAFLD or vice versa?Ester Vanni
Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, c so Bramante 88, 10126 Turin, Italy
Dig Liver Dis 42:320-30. 2010..Recently nuclear receptors have emerged as key regulators of lipid and carbohydrate metabolism for which specific pharmacological ligands are available, making them attractive therapeutic targets for NAFLD and NASH...
- Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liverElisabetta Bugianesi
Division of Gastro Hepatology, Department of Internal Medicine, University of Turin, Turin, Italy
Hepatology 39:179-87. 2004..Increased ferritin levels are markers of severe histologic damage, but not of iron overload. Iron burden and HFE mutations do not contribute significantly to hepatic fibrosis in the majority of patients with NAFLD...
- Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatmentElisabetta Bugianesi
Department of Gastroenterology, San Giovanni Battista Hospital, University of Turin, Corso Bramante 88, I 10127 Turin, Italy
Best Pract Res Clin Gastroenterol 18:1105-16. 2004..Large, long-term, placebo-controlled randomized studies are eagerly awaited. Outside controlled studies, nutritional counselling and physical exercise aimed at moderate weight loss remain the basis of any therapeutic intervention...
- Is liver disease a threat to patients with metabolic disorders?Giulio Marchesini
Unit of Metabolic Diseases, Alma Mater Studiorum University, Bologna, and San Giovanni Battista Hospital, Turin, Italy
Ann Med 37:333-46. 2005....
- The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver diseaseLuca Miele
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
Gastroenterology 135:282-291.e1. 2008..Based on its role in liver growth and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD progression...
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeGiulio Marchesini
Unit of Metabolic Diseases and Department of Internal Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
Hepatology 37:917-23. 2003..The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades...
- Non-alcoholic steatohepatitis in patients cared in metabolic unitsGiulio Marchesini
Unit of Metabolic Diseases, Department of Internal Medicine and Gastroenterology, University of Bologna, Alma Mater Studiorum, Via Massarenti 9, Policlinico S Orsola, I 40138 Bologna, Italy
Diabetes Res Clin Pract 63:143-51. 2004..Liver biopsy is recommended for diagnostic and prognostic purposes, as well as for testing treatment effects in controlled trials...
- Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: Another piece of the puzzleElisabetta Bugianesi
Hepatology 47:2-4. 2008
- Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in childrenValerio Nobili
Liver Unit, Research Institute, Bambino Gesu Children s Hospital, Piazza S Onofrio 4, 00165 Rome, Italy
Diabetes Care 30:2638-40. 2007
- Nonalcoholic fatty liver disease and the metabolic syndromeGiulio Marchesini
Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Italy
Curr Opin Lipidol 16:421-7. 2005..Insulin resistance is the common factor connecting obesity, diabetes, hypertension and dyslipidemia with fatty liver and the progression of hepatic disease to steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma...
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver diseaseNicola Villanova
Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138 Bologna, Italy
Hepatology 42:473-80. 2005..The risk of advanced liver disease is well recognized in NAFLD patients, but the large majority of cases might experience cardiovascular disease in the long term, indirectly limiting the burden of liver failure...
- Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control studyLuca Valenti
Department of Internal Medicine, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
Am J Gastroenterol 102:1251-8. 2007..Aims of this study were to define the relationship between ferritin and iron stores in patients with NAFLD, the effect of iron depletion on insulin resistance, and whether basal ferritin levels influence treatment outcome...